Previous close | 10.63 |
Open | 10.62 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's range | 10.62 - 10.64 |
52-week range | 9.71 - 11.15 |
Volume | |
Avg. volume | 12,293 |
Market cap | 161.75M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 118.17 |
EPS (TTM) | 0.09 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those cells to target and kill HIV instead of being “killed” by the virus. Thirty-eight million people are living with HIV globally, with 1.2 million in the U.S. and 2.3 million in Europe. Although HIV has suitable treatments, those treatments are expensive, lifelong, and can often have side effects.Addimmu
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those cells to target and kill HIV instead of being “killed” by the virus. Thirty-eight million people are living with HIV globally, with 1.2 million in the U.S and 2.3 million in Europe. Although HIV has suitable treatments, those treatments are expensive, lifelong, and can often have side effects.Addimmun
Sparks Energy, Inc. (“Sparks”), a power infrastructure services firm and a leader in power restoration management, has entered into a merger agreement with 10X Capital Venture Acquisition Corp. III (NYSE: VCXB) (“10X III”); the newly combined company will be listed on the New York Stock Exchange under the ticker symbol “SPKS”.Sparks provides critical electric transmission and distribution infrastructure recovery and repair services for utility customers across the United States, serving as the f